Your browser doesn't support javascript.
loading
Clinical and pathological characteristics of later onset multiple system atrophy.
Sekiya, Hiroaki; Koga, Shunsuke; Otsuka, Yoshihisa; Chihara, Norio; Ueda, Takehiro; Sekiguchi, Kenji; Yoneda, Yukihiro; Kageyama, Yasufumi; Matsumoto, Riki; Dickson, Dennis W.
Afiliação
  • Sekiya H; Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA. sekiya.hiroaki@mayo.edu.
  • Koga S; Division of Neurology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan. sekiya.hiroaki@mayo.edu.
  • Otsuka Y; Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.
  • Chihara N; Department of Neurology, Hyogo Prefectural Amagasaki General Medical Center Hospital, Amagasaki, Hyogo, Japan.
  • Ueda T; Division of Neurology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
  • Sekiguchi K; Division of Neurology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
  • Yoneda Y; Division of Neurology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
  • Kageyama Y; Department of Neurology, Hyogo Prefectural Amagasaki General Medical Center Hospital, Amagasaki, Hyogo, Japan.
  • Matsumoto R; Department of Neurology, Hyogo Prefectural Amagasaki General Medical Center Hospital, Amagasaki, Hyogo, Japan.
  • Dickson DW; Division of Neurology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
J Neurol ; 269(8): 4310-4321, 2022 Aug.
Article em En | MEDLINE | ID: mdl-35305144
ABSTRACT

BACKGROUND:

In the current consensus criteria, onset after age 75 is considered as non-supporting for diagnosis of multiples system atrophy (MSA); however, some MSA patients present after age 75. Clinical and pathological characteristics of such later onset MSA (LO-MSA) compared to usual onset MSA (UO-MSA) remain poorly understood.

METHODS:

The clinical cohort included patients from Kobe University Hospital and Amagasaki General Medical Center Hospital, while the autopsy cohort was from the brain bank at Mayo Clinic Florida. We identified 83 patients in the clinical cohort and 193 patients in the autopsy cohort. We divided MSA into two groups according to age at onset UO-MSA (≤ 75) and LO-MSA (> 75). We compared clinical features and outcomes between the two groups in the clinical cohort and compared the findings to the autopsy cohort.

RESULTS:

LO-MSA accounted for 8% in the clinical cohort and 5% in the autopsy cohort. The median time from onset to death or to life-saving tracheostomy was significantly shorter in LO-MSA than in UO-MSA in both cohorts (4.8 vs 7.9 years in the clinical cohort and 3.9 vs 7.5 years in the autopsy cohort; P = 0.043 and P < 0.0001, respectively). The median time from diagnosis to death was less than 3 years in LO-MSA in the clinical cohort.

CONCLUSIONS:

Some MSA patients have late age of onset and short survival, limiting time for clinical decision making. MSA should be considered in the differential diagnosis of elderly patients with autonomic symptoms and extrapyramidal and/or cerebellar syndromes.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Atrofia de Múltiplos Sistemas Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Atrofia de Múltiplos Sistemas Idioma: En Ano de publicação: 2022 Tipo de documento: Article